Delayed Nasdaq  -  04:00 2022-08-09 pm EDT
25.40 USD   -2.91%
08/08Morgan Stanley Cuts Maravai LifeSciences Holdings' Price Target to $35 From $49, Reiterates Overweight Rating
08/05MARAVAI LIFESCIENCES HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
08/05UBS Adjusts Maravai LifeSciences Holdings Price Target to $42 From $45, Maintains Buy Rating
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Maravai LifeSciences : Q2 2022 Maravai LifeSciences Earnings Presentation

08/04/2022 | 05:43pm EDT

Q2 2022 Financial Results

(Nasdaq: MRVI)

August 4, 2022

Today's Agenda




Financial Results & Guidance

Deb Hart, Head of Investor Relations

Kevin Herde, Chief Financial Officer


Business Highlights & Update


Q&A Session

Carl Hull, Chief Executive Officer

Carl Hull, Chief Executive Officer

Kevin Herde, Chief Financial Officer


Forward Looking Statements and Use of Non-GAAP Financial Measures

This presentation contains, and our officers and representatives may from time-to-time make, "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this presentation which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements regarding our financial guidance for 2022, strength of our business momentum, our pipeline and demand for our products including CleanCap® and NTPs, momentum of our non-COVID pipeline, strength and position of our IP portfolio, value prospects for our customers, customer growth for products and CDMO services, acceleration of development and production of GMP grade ultra pure nucleotides and expected strategic benefits of MyChem acquisition, growth in the number of vaccine and therapeutic assets in development and our ability to support the developers of these assets, efficacy and impact of cell and gene therapies, rate of approval for mRNA vaccine and therapeutics, demand for COVID-19-related vaccines and mRNA technology's role in such vaccines, COVID-vaccine related CleanCap demand in 2023, the value of our underlying business, our capabilities and their importance in future vaccine and therapeutic development, the commercial durability of our Nucleic Acid Production business, completion and benefits of our facilities expansions, potential organic and inorganic investments, and growth opportunities, constitute forward-looking statements and are identified by words like "believe," "expect," "may," "will," "should," "seek," "anticipate," or "could" and similar expressions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions and are not guarantees of the timing or nature of our future operating or financial performance or other events. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: Certain of our products are used by customers in the production of vaccines and therapies, some of which represent relatively new and still-developing modes of treatment. Unforeseen adverse events, negative clinical outcomes, development of alternative therapies or increased regulatory scrutiny of these vaccines and therapies and their financial cost may damage public perception of the safety, utility, or efficacy of these vaccines and therapies or other modes of treatment and may harm our customers' ability to conduct their business. Such events may negatively impact our revenue and have an adverse effect on our performance. Continued demand for our COVID-19 related products and services, which currently comprise a significant portion of our revenue, may decrease as populations are vaccinated, the COVID-19 pandemic subsides or antiviral therapeutic alternatives are developed successfully. We are dependent on our customers' spending on and demand for outsourced nucleic acid production and biologics safety testing products and services. A reduction in spending or demand could have a material adverse effect on our business, financial condition, results of operations, cash flows and prospects. We compete with life science, pharmaceutical and biotechnology companies who are substantially larger than we are and potentially capable of developing new approaches that could make our products, services and technology obsolete. We depend on a limited number of customers for a high percentage of our revenue. If we cannot maintain our current relationships with customers, fail to sustain recurring sources of revenue with our existing customers, or if we fail to enter into new relationships, our future operating results will be adversely affected. We rely on a limited number of suppliers or, in some cases, sole suppliers, for some of our raw materials and may not be able to find replacements or immediately transition to alternative suppliers. Such other factors as discussed throughout the "Risk Factors" section of our most recent Annual Report on Form 10-K, as well as other documents on file with the Securities and Exchange Commission. Any forward-looking statement made by us in this presentation is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

This presentation presents certain "non-GAAP Measures" as defined by the rules of the Securities Exchange Commission ("SEC") as a supplement to results presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"). These non-GAAP Measures, as well as other statistical measures, including Adjusted EBITDA (as defined herein) and Adjusted EBITDA as a percentage of revenues, are presented because the Company's management believes these measures provide additional information regarding the Company's performance and because we believe they are useful to investors in evaluating operating performance compared to that of other companies in our industry. In addition, management believes that these measures are useful to assess the Company's operating performance trends because they exclude certain material non-cash items, unusual or non-recurring items that are not expected to continue in the future, and certain other items. The non-GAAP Measures are not presented in accordance with GAAP, and the Company's computation of these non-GAAP Measures may vary from those used by other companies. These measures have limitations as an analytical tool and should not be considered in isolation or as a substitute or alternative to net income or loss, operating income or loss, cash flows from operating activities, total indebtedness or any other measures of operating performance, liquidity or indebtedness derived in accordance with GAAP. A reconciliation of historical non-GAAP Measures to historical GAAP measures and additional information on the Company's use of non-GAAP financial measures is provided on pages 27-29.

Past performance may not be a reliable indicator of future results.

This presentation also contains estimates and other statistical data made by independent parties and by the Company relating to market size and growth and other data about the Company's industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Neither the Company nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which the Company operates are necessarily subject to a high degree of uncertainty and risk.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of the products or services of Maravai LifeSciences Holdings, Inc. and its subsidiaries.


Q2 and 1H 2022

Business Highlights

& Update

Carl Hull

Chief Executive Officer

Q2 2022: A Great Quarter




$243 M

$188 M


per share

Base business growth of 4% (without COVID-19 CleanCap®)

  • Quarterly revenue, up 11% y/y
  • Adjusted EBITDA growth of 15% y/y
  • Record 78% adjusted EBITDA margin
  • Adjusted free cash flow of $175 M during the quarter


1. Reconciliations provided on pages 27-29

This is an excerpt of the original content. To continue reading it, access the original document here.


Maravai LifeSciences Holdings Inc. published this content on 04 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 04 August 2022 21:36:04 UTC.

© Publicnow 2022
08/08Morgan Stanley Cuts Maravai LifeSciences Holdings' Price Target to $35 From $49, Reiter..
08/05MARAVAI LIFESCIENCES HOLDINGS, INC. Management's Discussion and Analysis of Financial ..
08/05UBS Adjusts Maravai LifeSciences Holdings Price Target to $42 From $45, Maintains Buy R..
08/04MARAVAI LIFESCIENCES : Q2 2022 Maravai LifeSciences Earnings Presentation
08/04Maravai LifeSciences Holdings Posts Higher Q2 Earnings, Revenue; Updates 2022 Outlook
08/04TRANSCRIPT : Maravai LifeSciences Holdings, Inc., Q2 2022 Earnings Call, Aug 04, 2022
08/04Earnings Flash (MRVI) MARAVAI LIFESCIENCES HOLDINGS Reports Q2 EPS $0.54
08/04Earnings Flash (MRVI) MARAVAI LIFESCIENCES HOLDINGS Posts Q2 Revenue $242.7M
08/04CORRECTION : Maravai Lifesciences Reports Second Quarter 2022 Financial Results
08/04CORRECTION : Maravai Lifesciences Reports Second Quarter 2022 Financial Results
More news
More recommendations
Financials (USD)
Sales 2022 903 M - -
Net income 2022 305 M - -
Net cash 2022 190 M - -
P/E ratio 2022 21,8x
Yield 2022 0,39%
Capitalization 3 341 M 3 341 M -
EV / Sales 2022 3,49x
EV / Sales 2023 4,64x
Nbr of Employees 550
Free-Float 51,4%
Duration : Period :
Maravai LifeSciences Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 9
Last Close Price 25,40 $
Average target price 35,75 $
Spread / Average Target 40,7%
EPS Revisions
Managers and Directors
Carl W. Hull Chairman & Chief Executive Officer
Kevin M. Herde Chief Financial Officer & Executive Vice President
Mike Houston Chief Science Officer
Peter Michael Leddy Chief Administrative Officer & Executive VP
Anat Ashkenazi Independent Director
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-15.87%77 266
BIONTECH SE-28.97%41 143
WUXI APPTEC CO., LTD.-20.94%40 375